[{"address1": "100 Technology Center Drive", "address2": "Suite 300", "city": "Stoughton", "state": "MA", "zip": "02072", "country": "United States", "phone": "781 713 3699", "fax": "781 828 4697", "website": "https://www.collegiumpharma.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.", "fullTimeEmployees": 197, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.", "age": 59, "title": "Co-Founder, Chairman, Interim CEO & President", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 110000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Colleen  Tupper", "age": 47, "title": "Executive VP & CFO", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 782645, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shirley R. Kuhlmann", "age": 39, "title": "Executive VP, General Counsel, Chief Administrative Officer & Secretary", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 788451, "exercisedValue": 252974, "unexercisedValue": 513373}, {"maxAge": 1, "name": "Mr. Scott  Dreyer", "age": 51, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 693539, "exercisedValue": 0, "unexercisedValue": 956192}, {"maxAge": 1, "name": "Dr. Thomas B. Smith FAAFP, M.D.", "age": 62, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 693271, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher Shayne James M.D.", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bart J. Dunn", "title": "Executive Vice President of Strategy & Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Sudduth", "title": "Head of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 4, "shareHolderRightsRisk": 2, "overallRisk": 4, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 38.24, "open": 38.52, "dayLow": 37.55, "dayHigh": 39.26, "regularMarketPreviousClose": 38.24, "regularMarketOpen": 38.52, "regularMarketDayLow": 37.55, "regularMarketDayHigh": 39.26, "beta": 0.934, "trailingPE": 14.142857, "forwardPE": 5.5733333, "volume": 218037, "regularMarketVolume": 218037, "averageVolume": 470885, "averageVolume10days": 313250, "averageDailyVolume10Day": 313250, "bid": 37.52, "ask": 37.66, "bidSize": 100, "askSize": 200, "marketCap": 1211883136, "fiftyTwoWeekLow": 20.95, "fiftyTwoWeekHigh": 40.95, "priceToSalesTrailing12Months": 2.1015813, "fiftyDayAverage": 34.652, "twoHundredDayAverage": 33.7694, "currency": "USD", "enterpriseValue": 1519681792, "profitMargins": 0.17322999, "floatShares": 29459475, "sharesOutstanding": 32213800, "sharesShort": 6114082, "sharesShortPriorMonth": 6920209, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1898, "heldPercentInsiders": 0.0138, "heldPercentInstitutions": 1.25544, "shortRatio": 11.46, "shortPercentOfFloat": 0.2354, "bookValue": 6.701, "priceToBook": 5.614087, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.507, "netIncomeToCommon": 99893000, "trailingEps": 2.66, "forwardEps": 6.75, "pegRatio": 11.05, "enterpriseToRevenue": 2.635, "enterpriseToEbitda": 4.375, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "COLL", "underlyingSymbol": "COLL", "shortName": "Collegium Pharmaceutical, Inc.", "longName": "Collegium Pharmaceutical, Inc.", "firstTradeDateEpochUtc": 1431005400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ce084fc3-381a-311e-a750-8eb7c247886f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 37.62, "targetHighPrice": 50.0, "targetLowPrice": 37.0, "targetMeanPrice": 43.25, "targetMedianPrice": 43.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 271631008, "totalCashPerShare": 8.432, "ebitda": 347360000, "totalDebt": 559459008, "quickRatio": 0.987, "currentRatio": 1.105, "totalRevenue": 576652992, "debtToEquity": 258.312, "revenuePerShare": 17.637, "returnOnAssets": 0.11238, "returnOnEquity": 0.47866002, "freeCashflow": 263081120, "operatingCashflow": 276691008, "earningsGrowth": 0.523, "revenueGrowth": 0.072, "grossMargins": 0.86233, "ebitdaMargins": 0.60237, "operatingMargins": 0.32676, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]